Brief: Amarin Announces New Data Showing Benefit Of Vascepa In High-Risk Patients With A Recent Acute Coronary Syndrome Event
05/03/2023 15:28
March 5 (Reuters) - Amarin Corporation PLC AMRN.O :
* AMARIN ANNOUNCES NEW REDUCE-IT® DATA AT ACC.23/WCC SHOWING
BENEFIT OF VASCEPA®/VAZKEPA® (ICOSAPENT ETHYL) IN HIGH-RISK
PATIENTS WITH A RECENT ACUTE CORONARY SYNDROME EVENT
Source text for Eikon: ID:nGNX78gvBL
Further company coverage: AMRN.O
((Reuters.briefs@thomsonreuters.com;))
Recent news on Amarin
See all newsAmarin Corporation PLC reports results for the quarter ended June 30 - Earnings Summary
Ireland's Amarin Q2 revenue falls on lower licensing payments
Amarin Corporation PLC expected to post a loss of 1 cent a share - Earnings Preview
US Supreme Court backs generic drugmaker in 'skinny label' patent case (updated)
US Supreme Court backs generic drugmaker in 'skinny label' patent case